Ahead of Pending Studies on PGx-Based Plavix Administration, Is Quest/Scripps CYP2C19 Testing Alliance Premature? | GenomeWeb

By Turna Ray

WASHINGTON, DC — Quest Diagnostics' partnership with Scripps Health to offer CYP2C19 testing to stent procedure patients prior to treatment with the anti-platelet agent Plavix may be premature pending randomized controlled trials investigating the patient outcomes associated with testing, genomically guided Plavix dosing, and alternative treatments for CYP2C19 poor metabolizers, presenters at a conference on personalized medicine suggested this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.